全球再生醫療的市場

本報告提供全球的再生醫療市場--細胞治療、基因治療、生物組織治療、小分子與生技藥品4個部門--相關分析、各部門現在已上市/開發中的產品概要，及主要臨床實驗的進展、近幾年的市場趨勢、值得注意的企業簡介、今後的市場趨勢預測等調查，並將結果概述為以下內容。

第1章 摘要整理

• 摘要整理
• 變革市場結構的策略
• 分析方法、範圍

第2章 簡介

• 簡介
• 市場概況和明細
• 市場概況:細胞治療(CT)領域
• 市場概況:基因治療(GT)領域
• 市場概況:生物組織工程(TE)領域
• 市場概況:小分子、生技藥品領域

第3章 細胞治療部門

• 已上市產品的競爭環境
• 開發中的產品的競爭環境
• 市場分類
• 已上市產品的概要

第4章 細胞治療領域的已上市產品概要

• Apligraf (Organogenesis)
• GINTUIT (Organogenesis)
• Provenge (Dendreon)
• Grafix (Osiris Therapeutics)
• Dermagraft (Shire)
• Osteocel Plus (NuVasive)
• ReCell Spray-On Skin (Avita Medical)
• Trinity Evolution (Orthofix)
• BioDfactor (BioD, LLC)
• BioDfence (BioD, LLC)
• 細胞治療:開發平台概要

第5章 細胞治療部門:臨床實驗的主要里程碑

• 現在進展中/最近結束的臨床實驗概要

第6章 細胞治療部門:各企業的開發平台資產

• 開發平台的明細(共17家份)
• Aastrom Biosciences, Inc.
• Advanced Cell Technology, Inc.
• Aldagen, Inc. (Acquired by Cytomedix)
• Athersys, Inc.
• Celgene Cellular Therapeutics
• Cellerant Therapeutics, Inc.
• Gamida Cell Ltd.
• Garnet BioTherapeutics
• Histogenics
• Mesoblast Ltd.
• Neuralstem, Inc.
• Osiris Therapeutics, Inc.
• Pluristem Therapeutics, Inc.
• SanBio, Inc.
• StemCells, Inc.
• TCA Cellular Therapy, LLC
• TiGenix NV

第7章 基因治療部門

• 基因治療概要
• 值得注意的企業:Juventas Therapeutics Inc.

第8章 生物組織工程部門

• 生物組織工程概要

第9章 小分子、生技藥品部門

• 小分子、生技藥品概要

第10章 值得注意的企業:治療領域

• 心血管疾病(CVD)市場
• 血管疾病市場
• 非治癒性創傷市場
• 脊髓損傷市場
• 老年癡呆症市場
• 帕金森氏症(PD)市場
• 肌肉骨骼市場
• 自體免疫異常市場
• 中風市場
• 糖尿病市場
• 眼科疾病市場

第11章 近幾年的市場主要動向:時間軸

第12章 企業合併、收購(M&A)及企業聯盟(夥伴關係)的評估

第13章 資金籌措方案

第14章 結論

• 結論與建議
• 法律上的免責聲明

第15章 附錄

第16章 關於FROST & SULLIVAN

A New Era in Human Health to Resolve Unmet Medical Needs

This research service focuses on the 4 broad segments of the regenerative medicine market, namely cell therapy, gene therapy, tissue engineering, and small molecules and biologics. A detailed overview of the cell therapy segment, including the major commercialised products and products in development, has been provided. Additionally, key clinical milestones, timelines of key clinical events, key companies to watch, and a strategic partnership assessment in the global regenerative market have been included. An overview of the other segments-gene therapy, tissue engineering, and small molecules and biologics-has also been provided.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

• Executive Summary
• Executive Summary (continued)
• Regenerative Medicine Market-Game-changing Strategies
• Methodology and Scope

2. INTRODUCTION

Introduction

• Introduction
• Introduction (continued)
• Introduction (continued)
• Market Overview-Segmentation
• Market Overview-Cell Therapy (CT)Segment
• Market Overview-Cell Therapy (CT)Segment (continued)
• Market Overview-Cell Therapy (CT)Segment (continued)
• Market Overview-Cell Therapy (CT)Segment (continued)
• Market Overview-Gene Therapy (GT) Segment
• Market Overview-Tissue Engineering (TE) Segment
• Market Overview-Small Molecules and Biologics Segment

3. CELL THERAPY REGENERATIVE MEDICINE SEGMENT

Cell Therapy Regenerative Medicine Segment

• Cell Therapy-Competitive Landscape of Marketed Products
• Cell Therapy-Competitive Landscape of Products in Development
• Cell Therapy-Market Segmentation
• Cell Therapy-Marketed Products Synopsis
• Cell Therapy-Marketed Products Synopsis (continued)
• Cell Therapy-Marketed Products Synopsis (continued)
• Cell Therapy-Marketed Products Synopsis (continued)

4. PRODUCT DASHBOARD OF LEADING COMMERCIAL CELL THERAPY REGENERATIVE PRODUCTS

Product Dashboard of Leading Commercial Cell Therapy Regenerative Products

• Product Dashboard-Apligraf (Organogenesis)
• Product Dashboard-GINTUIT (Organogenesis)
• Product Dashboard-Provenge (Dendreon)
• Product Dashboard-Grafix (Osiris Therapeutics)
• Product Dashboard-Dermagraft (Shire)
• Product Dashboard-Osteocel Plus (NuVasive)
• Product Dashboard-ReCell Spray-On Skin (Avita Medical)
• Product Dashboard-Trinity Evolution (Orthofix)
• Product Dashboard-BioDfactor (BioD, LLC)
• Product Dashboard-BioDfence (BioD, LLC)
• Cell Therapy-Pipeline Synopsis
• Cell Therapy-Pipeline Synopsis (continued)
• Cell Therapy-Pipeline Synopsis (continued)
• Cell Therapy-Pipeline Synopsis (continued)
• Cell Therapy-Pipeline Synopsis (continued)
• Cell Therapy-Pipeline Synopsis (continued)
• Cell Therapy-Pipeline Synopsis (continued)
• Cell Therapy-Pipeline Synopsis (continued)

5. CELL THERAPY REGENERATIVE MEDICINE SEGMENT-MAJOR CLINICAL MILESTONES

Cell Therapy Regenerative Medicine Segment-Major Clinical Milestones

• Cell Therapy Regenerative Medicine Segment-Major On-going/Recently Completed Clinical Trials
• Cell Therapy Regenerative Medicine Segment-Major On-going/Recently Completed Clinical Trials (continued)
• Cell Therapy Regenerative Medicine Segment-Major On-going/Recently Completed Clinical Trials (continued)
• Cell Therapy Regenerative Medicine Segment-Major On-going/Recently Completed Clinical Trials (continued)
• Cell Therapy Regenerative Medicine Segment-Major On-going/Recently Completed Clinical Trials (continued)

6. CELL THERAPY REGENERATIVE MEDICINE SEGMENT-PIPELINE ASSETS BY COMPANY

Cell Therapy Regenerative Medicine Segment-Pipeline Assets by Company

• Cell Therapy-Pipeline Breakdown
• Company-Aastrom Biosciences, Inc.
• Company-Advanced Cell Technology, Inc.
• Company-Aldagen, Inc. (Acquired by Cytomedix)
• Company-Athersys, Inc.
• Company-Celgene Cellular Therapeutics
• Company-Cellerant Therapeutics, Inc.
• Company-Gamida Cell Ltd.
• Company-Garnet BioTherapeutics
• Company-Histogenics
• Company-Mesoblast Ltd.
• Company-Neuralstem, Inc.
• Company-Osiris Therapeutics, Inc.
• Company-Pluristem Therapeutics, Inc.
• Company-SanBio, Inc.
• Company-StemCells, Inc.
• Company-TCA Cellular Therapy, LLC
• Company-TiGenix NV

7. GENE THERAPY REGENERATIVE MEDICINE SEGMENT

Gene Therapy Regenerative Medicine Segment

• Gene Therapy Overview
• Gene Therapy Overview (continued)
• Gene Therapy Overview (continued)
• Key Company to Watch-Juventas Therapeutics Inc.

8. TISSUE ENGINEERING REGENERATIVE MEDICINE SEGMENT

Tissue Engineering Regenerative Medicine Segment

• Tissue Engineering Overview
• Tissue Engineering Overview (continued)
• Tissue Engineering Overview (continued)
• Tissue Engineering Overview (continued)
• Tissue Engineering Overview (continued)

9. SMALL MOLECULES AND BIOLOGICS REGENERATIVE MEDICINE SEGMENT

Small Molecules and Biologics Regenerative Medicine Segment

• Small Molecules and Biologics Overview
• Small Molecules and Biologics Overview (continued)

10. REGENERATIVE MEDICINE MARKET-KEY COMPANIES TO WATCH BY THERAPEUTIC SEGMENTS

Regenerative Medicine Market-Key Companies to Watch by Therapeutic Segments

• Cardiovascular Disease (CVD) Regenerative Medicine Market
• Cardiovascular Disease (CVD) Regenerative Medicine Market (continued)
• Cardiovascular Disease (CVD) Regenerative Medicine Market (continued)
• Vascular Disease Regenerative Medicine Market
• Vascular Disease Regenerative Medicine Market (continued)
• Non-Healing Wounds Regenerative Medicine Market
• Non-Healing Wounds Regenerative Medicine Market (continued)
• Spinal Cord Injury Regenerative Medicine Market
• Spinal Cord Injury Regenerative Medicine Market (continued)
• Spinal Cord Injury Regenerative Medicine Market (continued)
• Alzheimer's Disease Regenerative Medicine Market
• Alzheimer's Disease Regenerative Medicine Market (continued)
• Parkinson's Disease (PD) Regenerative Medicine Market
• Musculoskeletal Regenerative Medicine Market
• Musculoskeletal Regenerative Medicine Market (continued)
• Musculoskeletal Regenerative Medicine Market (continued)
• Autoimmune Disorders Regenerative Medicine Market
• Autoimmune Disorders Regenerative Medicine Market (continued)
• Autoimmune Disorders Regenerative Medicine Market (continued)
• Stroke Regenerative Medicine Market
• Stroke Regenerative Medicine Market (continued)
• Diabetes Regenerative Medicine Market
• Diabetes Regenerative Medicine Market (continued)
• Ocular Diseases Regenerative Medicine Market
• Ocular Diseases Regenerative Medicine Market (continued)

11. REGENERATIVE MEDICINE MARKET-TIMELINE OF KEY EVENTS

Regenerative Medicine Market-Timeline of Key Events

• Regenerative Medicine Market-Timeline of Key Events
• Regenerative Medicine Market-Timeline of Key Events (continued)
• Regenerative Medicine Market-Timeline of Key Events (continued)
• Regenerative Medicine Market-Timeline of Key Events (continued)

12. REGENERATIVE MEDICINE MARKET-MERGER, ACQUISITION, AND PARTNERSHIP ASSESSMENT

Regenerative Medicine Market-Merger, Acquisition, and Partnership Assessment

• Regenerative Medicine Market-Merger, Acquisition, and Partnership Assessment
• Regenerative Medicine Market-Merger, Acquisition, and Partnership Assessment (continued)
• Regenerative Medicine Market-Merger, Acquisition, and Partnership Assessment (continued)
• Regenerative Medicine Market-Merger, Acquisition, and Partnership Assessment (continued)

13. REGENERATIVE MEDICINE MARKET-FUNDING SCENARIO

Regenerative Medicine Market-Funding Scenario

• Regenerative Medicine Market-Funding Scenario
• Regenerative Medicine Market-Funding Scenario (continued)
• Regenerative Medicine Market-Funding Scenario (continued)
• Regenerative Medicine Market-Funding Scenario (continued)

14. CONCLUSIONS

Conclusions

• Conclusions and Recommendations
• Legal Disclaimer

15. APPENDIX

Appendix

• Human Embryonic Stem Cells Overview
• Mesenchymal Stem Cells Overview
• Neural Stem Cells Overview
• Induced Pluripotent Stem Cells Overview
• Stem Cell Types in Development
• List of Abbreviations

16. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

• The Frost & Sullivan Story
• Value Proposition
• Global Perspective
• Industry Convergence
• 360° Research Perspective
• Implementation Excellence
• Our Blue Ocean Strategy